[
  "Johnson & Johnson announces first head-to-head study comparing IMAAVYâ„¢ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting",
  "Freedom Capital Downgrades Johnson & Johnson (JNJ) to Hold Despite Strong Q3 Results"
]